Shares of Bellerophon Therapeutics Inc (NASDAQ:BLPH) have been given an average broker rating score of 1.00 (Strong Buy) from the one brokers that cover the company, Zacks Investment Research reports. One investment analyst has rated the stock with a strong buy rating.
Brokers have set a twelve-month consensus price objective of $3.00 for the company and are anticipating that the company will post ($0.12) EPS for the current quarter, according to Zacks. Zacks has also assigned Bellerophon Therapeutics an industry rank of 112 out of 255 based on the ratings given to related companies.
BLPH has been the subject of a number of analyst reports. ValuEngine raised shares of Bellerophon Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, June 8th. HC Wainwright reaffirmed a “buy” rating and set a $3.00 target price on shares of Bellerophon Therapeutics in a research note on Thursday, August 9th. Finally, Zacks Investment Research downgraded shares of Bellerophon Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, July 11th.
An institutional investor recently bought a new position in Bellerophon Therapeutics stock. DRW Securities LLC purchased a new stake in shares of Bellerophon Therapeutics Inc (NASDAQ:BLPH) during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 70,000 shares of the biotechnology company’s stock, valued at approximately $146,000. DRW Securities LLC owned about 0.12% of Bellerophon Therapeutics as of its most recent SEC filing. Hedge funds and other institutional investors own 58.49% of the company’s stock.
Shares of NASDAQ BLPH opened at $1.07 on Wednesday. Bellerophon Therapeutics has a fifty-two week low of $0.47 and a fifty-two week high of $3.30. The company has a market cap of $68.20 million, a price-to-earnings ratio of -1.19 and a beta of -0.80.
Bellerophon Therapeutics (NASDAQ:BLPH) last announced its earnings results on Wednesday, August 1st. The biotechnology company reported ($0.20) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.10) by ($0.10). equities research analysts expect that Bellerophon Therapeutics will post -0.4 EPS for the current fiscal year.
Bellerophon Therapeutics Company Profile
Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products at the intersection of drugs and devices for the treatment of cardiopulmonary diseases. The company offers INOpulse, a pulsatile nitric oxide delivery device, which is in Phase III clinical trials for the treatment of pulmonary arterial hypertension; and has completed Phase II clinical trials to treat pulmonary hypertension associated with chronic obstructive pulmonary diseases and pulmonary hypertension associated with idiopathic pulmonary fibrosis.
Featured Article: Leveraged Buyout (LBO)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Bellerophon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.